IGC to be Featured in Feb. 10 Radius Research Investor Webinar
India Globalization Capital (NYSE American: IGC) announces an upcoming investor webinar featuring CEO Ram Mukunda and PFO Claudia Grimaldi on February 10, 2023, at 12:30 p.m. ET. They will discuss the Company’s Phase 2 trial for IGC-AD1, aimed at alleviating agitation in Alzheimer's patients. The trial involves 146 participants and is categorized as Phase 2B for safety and efficacy. IGC is focused on developing cannabinoid-based formulations for various conditions, including Alzheimer’s disease. The Company also markets wellness brands Holief and Sunday Seltzer.
- Upcoming investor webinar scheduled for February 10, 2023, to discuss IGC-AD1.
- Phase 2B trial for IGC-AD1 involves 146 participants, focusing on agitation in Alzheimer's patients.
- IGC has demonstrated potential effectiveness of drug candidates in Alzheimer's cell lines.
- Dependence on successful commercialization and regulatory approval of IGC-AD1 and other products.
- Risks associated with general economic conditions, including impacts from the COVID-19 pandemic.
POTOMAC, Md., Feb. 08, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces that Ram Mukunda, CEO, and Claudia Grimaldi, PFO, will be featured in an investor webinar hosted by Radius Research on Friday, Feb. 10, at 12:30 p.m. ET. They will discuss the Company’s Phase 2 trial for its drug candidate IGC-AD1 in treating agitation in dementia patients suffering from Alzheimer’s and will participate in a question and answer session.
Investors can register for the webinar at this link: https://us02web.zoom.us/webinar/register/2516753795488/WN_D5lza7ihQd6SUJEi0ay5_Q
About IGC
IGC develops advanced cannabinoid-based formulations for treating diseases and conditions including but not limited to Alzheimer’s disease, period cramps (dysmenorrhea), premenstrual syndrome (PMS), and chronic pain. The Company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, that have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease such as plaques and tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is currently in a 146-person Phase 2B safety and efficacy clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). The Company also markets two wellness brands, Holief and Sunday Seltzer. Holief targets women experiencing premenstrual syndrome and menstrual cramps and Sunday Seltzer is a lifestyle hemp-infused energy beverage brand. The Company has historically operated an infrastructure segment based in India. The Company is headquartered in Maryland, USA.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required; general economic conditions that are less favourable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s U.S. Securities and Exchange Commission (“SEC”) filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 23, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact:
IMS Investor Relations
Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
FAQ
What is the purpose of the IGC webinar on February 10, 2023?
What is IGC-AD1?
How many participants are involved in the IGC-AD1 clinical trial?
What are the main drug candidates being developed by IGC?
What wellness brands does IGC market?
